US pharmaceutical firm Bristol-Myers Squibb has agreed a deal to buy biotechnology company Amylin Pharmaceuticals in a move that will help expand its diabetes treatments portfolio.
In an announcement on Friday night, Bristol-Myers said it will pay around $5.3 billion (£3.8bn) in cash for the acquisitio, $3.4 billion (£2.2bn) of which will come from UK-based AstraZeneca Plc as part of a follow-on deal that will see the pair combine their development, regulatory and commercial strengths “to unlock the potential” of Amylin’s products.
These include Byetta, a twice-daily injectable medication for people with type 2 diabetes, and Bydureo, the longer-acting version of the Byetta that requires just one injection a week.

The move will form part of Bristol and AstraZeneca’s long-standing diabetes drugs partnership, and is aimed at strengthening their position in a growing, multi-billion pound market.
In a statement, Bristol-Myers chief executive Lamberto Andreotti said: “We are pleased to be able to strengthen the portfolio we have built to help patients with diabetes.”
“The acquisition of Amylin by Bristol-Myers Squibb is also a unique way for Bristol-Myers Squibb and AstraZeneca to expand the alliance between the two companies, and it demonstrates Bristol-Myers Squibb’s innovative and targeted approach to partnerships and business development.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…